Taisho Pharmaceutical Pabron Gold A (Granules) unlicensed product:, product is labelled to contain dihydrocodeine phosphate that is listed on Schedule I of the CDSA

Product safety

Date

2024-06-10

Country

Canada

Product

Taisho Pharmaceutical Pabron Gold A (Granules)

Classification

Type II

Category

Drugs & medical

Source

Health Canada

Copied automatically from the Government of Canada. Details may be shortened or out of date; the official notice is the authoritative source. Disclaimer

What to do

1. Check the product name, strength and lot number against the official notice.
2. Do not stop a prescribed medicine without talking to your doctor or pharmacist first.
3. Ask the pharmacy or supplier about a replacement or refund.

General guidance from Recall Atlas. The official notice from the Government of Canada has the exact models, batch codes and remedy, and it takes priority.

Other drugs & medical recalls in Canada

1. 2024-06-13
2. CA
   Drugs & medicalType I

   Philips SENSE XL Torso (1.5T and 3.0T) coils

   Performance

   Health CanadaOfficial notice →
3. 2024-06-12
4. CA
   Drugs & medicalType II

   Zyn Nicotine Pouches 1.5 & 3mg: No market authorization

   Product safety

   Health CanadaOfficial notice →
5. 2024-06-10
6. CA
   Drugs & medicalType I

   BLUSelect®, BLUgriggs® and BLUperc® Products

   Performance

   Health CanadaOfficial notice →
7. 2024-06-07
8. CA
   Drugs & medicalType I

   PMS-PIRFENIDONE 267 & 801 mg: Data integrity concerns with products bioequivalence data that could lead to incorrect dosing.

   Product quality

   Health CanadaOfficial notice →
9. CA
   Drugs & medicalType II

   DELFIA / AutoDELFIA PIGF 1-2-3

   Performance

   Health CanadaOfficial notice →
10. CA
    Drugs & medicalType II

    Beckman Coulter Au Immunochemistry System- Immunoglobulin M (IgM)

    Performance

    Health CanadaOfficial notice →